{"id":"NCT05062330","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","officialTitle":"The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-28","primaryCompletion":"2022-03-04","completion":"2022-03-04","firstPosted":"2021-09-30","resultsPosted":"2025-03-18","lastUpdate":"2025-03-18"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%)","otherNames":[]},{"type":"DRUG","name":"Vehicle Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic Solution administered 7 times over two consecutive days","type":"PLACEBO_COMPARATOR"}],"summary":"The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease","primaryOutcome":{"measure":"Schirmer Test Mean Change From Baseline","timeFrame":"The efficacy assessment period was before and after the final dose on Day 1 (Dose 4). Baseline was approximately two weeks before dosing at Screening.","effectByArm":[{"arm":"Reproxalap","deltaMin":1.8,"sd":0.4},{"arm":"Vehicle","deltaMin":-0.5,"sd":0.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":181},"commonTop":["General disorders and administration site conditions"]}}